The Relative Strength (RS) Rating for Mineralys Therapeutics moved into a higher percentile Thursday, as it got a lift from 64 to 75.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an RS Rating north of 80 as they begin their biggest price moves. See if Mineralys Therapeutics can continue to rebound and hit that benchmark.
Mineralys Therapeutics is working on a cup with handle with a 16.90 buy point. See if it can break out in volume at least 40% higher than normal.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
The company earns the No. 285 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
